MARKET

AIM

AIM

Aim Immunotech
AMEX
0.2800
-0.0099
-3.42%
Closed 15:58 07/10 EDT
OPEN
0.2913
PREV CLOSE
0.2899
HIGH
0.2913
LOW
0.2800
VOLUME
268.31K
TURNOVER
--
52 WEEK HIGH
19.72
52 WEEK LOW
0.2100
MARKET CAP
7.76M
P/E (TTM)
-0.0379
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AIM last week (0629-0703)?
Weekly Report · 4d ago
Weekly Report: what happened at AIM last week (0622-0626)?
Weekly Report · 06/29 09:52
AIM ImmunoTech Outlines Upcoming Milestones, Including DURIPANC Primary Endpoint Analysis Expected In December 2026
Benzinga · 06/24 12:31
Weekly Report: what happened at AIM last week (0615-0619)?
Weekly Report · 06/22 09:58
AIM Advances Phase 2 DURIPANC Study In Pancreatic Cancer; Expects Topline Data In Q1,2027
NASDAQ · 06/22 09:44
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
Barchart · 06/22 07:45
AIM ImmunoTech Regains NYSE Compliance With Increased Stockholders' Equity
NASDAQ · 06/16 09:03
AIM ImmunoTech Regains NYSE American Listing Compliance
TipRanks · 06/15 12:36
More
About AIM
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's flagship product Ampligen is a double-stranded ribonucleic acid (dsRNA) molecule being developed for globally important cancers, viral diseases and disorders of the immune system. The Alferon N Injection (Interferon alfa) is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older. It is also approved in Argentina for the treatment of refractory patients that failed or were intolerant to treatment with recombinant interferons. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS).

Webull offers AIM ImmunoTech Inc stock information, including AMEX: AIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AIM stock methods without spending real money on the virtual paper trading platform.